Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

Bagsværd, Denmark (ots/PRNewswire) -

- Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in
people with controlled blood sugar levels
- In people with diabetes whose blood sugar was too high, switching
to Tresiba® significantly improved blood sugar levels

Switching to Tresiba® from another basal insulin benefits people
with diabetes regardless of whether or not their blood sugar levels
are controlled.[1] This is the conclusion of a post-hoc analysis of
data from the EU-TREAT study collected in a real-world clinical
setting among people with type 1 and type 2 diabetes.

In people with type 2 diabetes whose blood sugar levels were
controlled (HbA1c <=7.5%) with basal insulin prior to switching,
Tresiba® significantly reduced the rate of hypoglycaemia (low blood
sugar levels) while maintaining blood sugar control. Results showed a
67% reduction in the rate of hypoglycaemic events over six months
after switching to Tresiba®, with an 11% lower dose of insulin.[1]

In patients with uncontrolled type 1 or type 2 diabetes, switching
to Tresiba® resulted in significantly improved glycaemic control
without an increase in the risk of hypoglycaemia or insulin
dose.[1][2] These results were sustained for up to 12 months after
switching from another basal insulin, mainly insulin glargine U100
and insulin detemir.[1]

In people with type 1 diabetes whose blood sugar levels were
controlled, a 16% lower rate of hypoglycaemia was observed over six
months, and blood sugar control was maintained with a 13% lower dose
of insulin.[1]

"This new analysis shows that people with diabetes who have
switched to Tresiba® in the real world benefit from this change,
regardless of whether they did so to improve blood glucose control or
reduce the risk of hypoglycaemia," said Mads Krogsgaard Thomsen,
executive vice president and chief science officer at Novo Nordisk.
"This confirms that the benefits of Tresiba® seen in clinical trials
are being reproduced in clinical practice."

The main results of the EU-TREAT real-world evidence study
reported earlier this year showed that that people with type 1 and
type 2 diabetes experienced a significant reduction in HbA1c six
months after switching to Tresiba®. Rates of overall hypoglycaemia
were also significantly lower at six months after switching to
Tresiba®. In people with type 1 diabetes, the rate of severe
hypoglycaemia was reduced by 85% and by 92% in people with type 2
diabetes. Similar reductions were seen at 12 months.[2,3]

About EU-TREAT

EU-TREAT (EUropean TREsiba AudiT) is a European, multicentre,
real-world evidence study (n=2,550) investigating the effect of
switching to Tresiba® from another basal insulin in people with type
1 (n=1,717) and type 2 (n=833) diabetes. Patients in Austria,
Denmark, Germany, Greece, Italy and Switzerland were switched from
another basal insulin to Tresiba® 6 months prior to data collection.
Outcome measurements were collected at 6±3 and 12±3 months after
initiation on Tresiba® and was compared to baseline measurement taken
from the prior basal insulin during a 3-month period prior to
initiation on Tresiba®. [2,3]

About Tresiba[® ]

Tresiba® (insulin degludec) is a once-daily basal insulin that
provides a duration of action beyond 42 hours with a flat and stable
glucose-lowering effect.[4,5] It provides low variability in blood
glucose levels and a lower risk of overall, nocturnal and severe
hypoglycaemia vs. insulin glargine U100.[4,6] On occasions when
administration at the same time of day is not possible, Tresiba®
allows for flexibility in day-to-day dosing time with a minimum of
eight hours between injections.[5] Tresiba® received its first
regulatory approval in September 2012 and has since been approved in
more than 80 countries globally. It is now commercially available in
more than 50 countries.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 41,700 people in 77 countries and markets its
products in more than 165 countries. For more information, visit
novonordisk.com (https://www.novonordisk.com/), Facebook
(https://www.facebook.com/novonordisk), Twitter
(https://mobile.twitter.com/novonordisk), LinkedIn
(https://www.linkedin.com/company/novo-nordisk), YouTube
(https://www.youtube.com/user/novonordisk/custom) .

Further information

Media:
Katrine Sperling +45-4442-6718 krsp@novonordisk.com
Åsa Josefsson +45-3079-7708 aajf@novonordisk.com

Investors:
Peter Hugreffe Ankersen +45-3075-9085 phak@novonordisk.com
Hanna Ögren +45-3079-8519 haoe@novonordisk.com
Anders Mikkelsen +45-3079-4461 armk@novonordisk.com
Christina Kjær +45-3079-3009 cnje@novonordisk.com
Kasper Veje (US) +1-609-235-8567 kpvj@novonordisk.com

References

1. Novo Nordisk. EU-TREAT post hoc analysis. Data on file. 2017.

2. Siegmund T, Tentolouris N, Knudsen TS, et al. EU-TREAT 1:
Switching to insulin degludec reduces the risk of hypoglycaemia in
patients with T1DM in a real-world setting. Poster presentation. 77th
Annual Scientific Sessions of the American Diabetes Association
(ADA), San Diego, California, US. June 2017.

3. Schultes B, Tentolouris N, Knudsen TS, et al. EU-TREAT 2:
Switching to insulin degludec improves glycaemic control in patients
with T2DM in a real-world setting. Poster presentation. 77th Annual
Scientific Sessions of the American Diabetes Association (ADA), San
Diego, California, US. June 2017.

4. EMA. Tresiba® Summary of Product Characteristics. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_I
nformation/human/002498/WC500138940.pdf (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf). Last accessed: December
2017.

5. Haahr H, Heise T. A review of the pharmacological properties of
insulin degludec and their clinical relevance. Clin Pharmacokinet.
2014; 53:787-800.

6. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of
degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;
377:723-732.

ZINC ID: HQMMA/TB/0917/0327: December 2017

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell